Delivery Order SPE2DB24D3015-SPE2DB25FGAXJ
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $21,030.84, with completion expected by August 21, 2025. This competitively awarded, non-set-aside delivery order represents a routine pharmaceutical procurement supporting federal medical supply needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Ibsrela 50 mg tablets (60 tablets per unit) under a firm fixed-price contract valued at $26,774.18. This non-set-aside delivery order is scheduled for completion by August 29, 2025, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- The U.S. Department of Defense Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) under a firm fixed-price contract valued at $3,784.00, with completion targeted for September 18, 2025. This is a competitively awarded, non-set-aside delivery order issued by the federal government's medical procurement division. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform...
- AmerisourceBergen Drug Corp was awarded a delivery order valued at $26,193.92 by the Defense Logistics Agency on August 7, 2025, for the supply of Ibsrela 50 mg tablets in quantities of 60 units. This is a firm fixed-price delivery order with no set-aside designation, indicating the award was made through open competition. The contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, with an ultimate completion date of August 8, 2025. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $5,086.77 to AmerisourceBergen Drug Corp for the supply of Ibsrela 50 mg tablets (60-count units) on August 28, 2025, with an ultimate completion date of August 29, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare...
- The Defense Logistics Agency awarded a $3,431.04 firm fixed-price delivery order to AmerisourceBergen Drug Corp on June 18, 2025, for the supply of Ibsrela 50 mg tablets (60-count units). This non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. Performance will be executed from the contractor's Conshohocken, Pennsylvania location,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Ibsrela 50 mg tablets (60-count unit) valued at $1,926.04. This firm fixed-price contract, which reaches completion on August 6, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion vehicle running through December 2026. The delivery order carries no set-aside...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on June 17, 2025, for the supply of Ibsrela 50 mg tablets (60-count units) with a ceiling value of $11,718.53. This firm fixed-price delivery order, which is due for completion by June 18, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The award was made through competitive...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Ibsrela 50 mg tablets (60 count) under a firm fixed-price contract valued at $4,847.75. This non-set-aside award is a child contract executed under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion vehicle that runs through December 2026 and supports pharmaceutical procurement for military and veteran...
- The Defense Logistics Agency awarded a delivery order valued at $3,047.31 to AmerisourceBergen Drug Corp for 60 tablets of Ibsrela 50 mg on June 27, 2025. This competitive award, issued without set-aside provisions, is structured as a firm fixed price delivery order with an ultimate completion date of June 30, 2025. The pharmaceutical product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen Drug Corp maintains its corporate office. This delivery order...
- SPE2DB24D3015Indefinite Delivery Contract
- SPE2DB24D3015-SPE2DB25FGAXJDelivery Order
This delivery order, valued at $21,312.70, was awarded to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Ibsrela 50 mg tablets in 60-count units to support federal medical procurement needs. The contract is non-competitive and utilizes firm fixed pricing with an ultimate completion date of September 10, 2025. The Defense Logistics Agency, which serves as the funding federal agency, awarded this order to supply pharmaceutical products to support military and veteran healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. This prime contract vehicle enables the company to provide a comprehensive range of pharmaceutical products and medical supplies to military healthcare programs globally, including specialty medications, brand-name and generic drugs, and other critical medical commodities. The place of performance is located in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and primary distribution operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $21.3k | 9/9/25 |